Latest Biotech News

Novo Nordisk reported an updated outlook for its Wegovy oral launch, saying sales and profit will decline less than originally expected due to stronger-than-forecast prescriptions. The company’s...

Madrigal Pharmaceuticals extended its MASH strategy with another Arrowhead Pharmaceuticals deal, securing licensing rights for an siRNA candidate targeting a genetic driver tied to metabolic...

Resmed agreed to acquire Noctrix Health for $340 million, adding a wearable neuromodulation option for restless legs syndrome to its sleep health portfolio. Noctrix’s Nidra device aims to treat...

Mayo Clinic and Stanford Medicine developed a first blood test intended to chart tumor “neighborhoods” and predict therapy response by analyzing the microenvironment surrounding cancer cells. The...

Tempus AI reported Q1 revenue of $348.1 million, up 36% year over year, and raised full-year guidance on the back of stronger diagnostics volume. The company highlighted minimal residual disease...

Johns Hopkins physicians reported a ~95% cure rate for sickle cell disease using a bone marrow transplant protocol developed through the Johns Hopkins Kimmel Cancer Center. The approach uses...

BeOne Medicines said it is cutting five cancer programs while moving an autoimmune Phase 2 asset forward, reflecting a pipeline reset as it carries 18 molecular entities across 2024 and 2025...

Moonlight AI, a Swiss developer of diagnostic image-analysis tools, raised $3.3 million in private financing to expand its library of whole-slide cytopathology images linked to genomic data. The...

Bayer moved to expand its ophthalmology franchise, agreeing to buy Perfuse Therapeutics in a deal valuing the transaction at up to $2.4B, including up to $2.15B in milestones, according to reports...

UCB agreed to acquire Candid Therapeutics for up to $2.2B, adding the company’s clinical-stage T-cell engager and expanding UCB’s autoimmune immunology pipeline. The transaction is structured...

Madrigal Pharmaceuticals extended its metabolic dysfunction–associated steatohepatitis (MASH) expansion with additional licensing activity linked to Arrowhead Pharmaceuticals’ siRNA assets,...

Novo Nordisk reported that strong prescription performance for its oral obesity therapy boosted demand, leading the company to revise expectations upward as it released earnings and guidance...

ChromaGenix, an NC State spinout, launched a commercial platform built around synthetic peptide ligands for purifying viral vectors used in gene therapies and other biologic manufacturing. The...

Prolific Machines reported a manufacturing productivity milestone using a light-controlled, optogenetics-driven CHO platform, posting a 21 g/L titer in a 15-day intensified fed-batch run for a...

OpenBind, a UK-led initiative for AI-enabled drug discovery, released its first publicly available dataset and predictive AI model, a step meant to accelerate new target-to-lead exploration. The...

Applied BioCode announced expanded FDA 510(k) clearance for its BioCode Respiratory Pathogen Panel, adding automated extraction using Thermo Fisher Scientific’s KingFisher Flex platform. The...

Adaptive Biotechnologies raised full-year 2026 revenue guidance for its minimal residual disease (MRD) business after reporting continued momentum in Q1. The company now expects MRD revenue...

Grail reported Q1 revenue up 28% year over year, driven by growth in its Galleri multi-cancer early detection blood test. Revenue tied to Galleri reached $39.8M, and test volume increased 37% with...

UCB agreed to acquire Candid Therapeutics for up to $2.2 billion, extending the Belgian company’s push into immune-mediated disease with next-generation T-cell engagers. The upfront consideration...

Tempus AI reported a 36% year-over-year jump in Q1 revenue to $348.1 million and raised its full-year guidance, pointing to continued demand for its AI-enabled diagnostic platform. Diagnostics...